Bladder-cancer therapy developer CG Oncology filed for an preliminary public providing with the Securities and Exchange Commission.
The Irvine, Calif.-based biopharmaceutical firm is growing a possible therapeutic for bladder-cancer sufferers who’re unresponsive to immunotherapy Bacillus Calmette-Guerin therapy.
CG Oncology didn’t say what number of shares it deliberate to supply or give an estimated worth vary. The firm plans to make use of proceeds primarily for supporting operations.
The firm has utilized to listing its shares on the Nasdaq Global Market underneath the ticker CGON.
Morgan Stanley, Goldman Sachs & Co., Cantor and Lifesci Capital are appearing because the underwriters of the providing.
Source web site: www.marketwatch.com
